CPHI
China Pharma Holdings IncAMEX
Healthcare • Drug Manufacturers - Specialty & Generic
$0.57+7.53%
Close Nov 6, 2026
- Market cap
- $24.52M
- 1 month
- -40.6%
- 3 months
- -49.1%
- 1 year
- -96.1%
- 52-week range
- $0.52$8.10
- Dividend
- No dividends on record
- Short interest
- 6.0% of float198.3K shares · settled Oct 15, 2026 · +220.5% since Sep 30, 2026 · FINRA
Fundamentals · trailing 12 months to Jun 30, 2026
- Revenue
- $3.91M
- Net income
- -$4.47M
- Free cash flow
- -$219.48K
- Book value
- $36.18M
- Total debt
- $3.75M
- P/E
- —
- Price / sales
- 6.3×
- Price / book
- 0.7×
- FCF yield
- -0.9%
- Net margin
- -114.3%
EODHD (TTM) · as of Nov 6, 2026
End-of-day close from stored market data, not a live quote.
About China Pharma Holdings Inc
China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical products for human use in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions.
Read more
Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection for edema diseases, hypertension, acute renal failure, hyperkalemia, hypercalcemia, and acute drug poisoning; and Candesartan for hypertension. It offers Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and Pseudophedrine Hydrochlorida sustained release tablets, as well as Hepatocyte growth-promoting factors, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. In addition, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection for nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It supplies its products to hospitals and OTC pharmacies through provincial and municipal pharmaceutical logistics companies. The company is based in Haikou, the People's Republic of China.
- Website
- chinapharmaholdings.com
- Headquarters
- Haikou, China
- Employees
- 215
- Listed
- Apr 17, 2002
- Fiscal year ends
- December
Company profile from EODHD, stored Nov 3, 2026.
Quarterly results
The last 8 fiscal quarters as reported (EODHD). Year over year compares the same quarter a year earlier.
| Quarter | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Jun 2026filed Aug 14, 2026 | $948.3K | -7.5% | 8.8% | -$1.4M | -$1.5M |
| Mar 2026filed May 15, 2026 | $983.5K | -13.4% | -54.9% | -$1.1M | -$1.1M |
| Dec 2025 | $1.2M | +8.1% | 12.3% | -$1.2M | -$1.2M |
| Sep 2025filed Nov 12, 2025 | $756.2K | -31.3% | -7.9% | -$628.1K | -$651.5K |
| Jun 2025filed Aug 14, 2025 | $1.0M | +10.9% | -8.5% | -$652.1K | -$528.4K |
| Mar 2025 | $1.1M | -17.0% | -12.0% | -$758.6K | -$785.6K |
| Dec 2024filed Mar 31, 2025 | $1.1M | -47.2% | -4.9% | -$1.2M | -$1.2M |
| Sep 2024filed Nov 13, 2024 | $1.1M | -39.0% | -47.2% | -$1.1M | -$1.1M |
Fiscal years · last 6
| Fiscal year | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Dec 2025filed Apr 1, 2026 | $4.1M | -8.5% | -3.2% | -$3.1M | -$3.2M |
| Dec 2024filed Mar 31, 2025 | $4.5M | -35.4% | -43.8% | -$4.6M | -$4.7M |
| Dec 2023filed Apr 1, 2024 | $7.0M | -13.5% | -4.0% | -$2.8M | -$3.1M |
| Dec 2022filed Mar 30, 2023 | $8.1M | -15.9% | -6.1% | -$3.5M | -$4.0M |
| Dec 2021filed Mar 30, 2022 | $9.6M | -11.3% | 3.6% | -$2.9M | -$3.4M |
| Dec 2020filed Mar 26, 2021 | $10.9M | -0.5% | 18.0% | -$2.6M | -$2.9M |
Short-interest history
FINRA reports open short positions for a settlement date. The publication date is later. These are reported positions, with a separate date for each observation.
Compare the reported short exposure around the dates you bought, sold or watched CPHI. A long position benefits from price rises; a short position benefits from falls. A change in these counts does not predict either move.
Settlement Oct 15, 2026
198,256 shares short
+136,397 shares (+220.5%) vs Sep 30, 2026
6% of the stored float. Published Oct 26, 2026.
Settlement Sep 30, 2026
61,859 shares short
-120,751 shares (-66.1%) vs Sep 15, 2026
1.9% of the stored float. Published Oct 9, 2026.
Settlement Sep 15, 2026
182,610 shares short
-13,161 shares (-6.7%) vs Aug 31, 2026
22.8% of the stored float. Published Sep 24, 2026.
Settlement Aug 31, 2026
195,771 shares short
-427,991 shares (-68.6%) vs Aug 14, 2026
Share of float unavailable. Published Sep 10, 2026.
Settlement Aug 14, 2026
623,762 shares short
+508,100 shares (+439.3%) vs Jul 31, 2026
Share of float unavailable. Published Aug 25, 2026.
Settlement Jul 31, 2026
115,662 shares short
-298,181 shares (-72.1%) vs Jul 15, 2026
Share of float unavailable. Published Aug 11, 2026.
Change = this settlement’s shares short − the previous recorded settlement’s shares short; percentage change divides by that earlier count. A zero earlier count has no percentage change. Split-spanning counts are left uncompared. Float percentages use the stored settlement observation, not today’s float.
Source: stored FINRA equity short-interest records, up to six settlements from the last 240 days. FINRA data and reporting dates · How to read short interest
Dividends and stock splits
See the recorded cash amounts and dates behind CPHI’s income, and the splits that change its share count. Dates below are stored event records, not confirmation of a payment to your account.
Cash-dividend records
No qualified cash-dividend records are stored. This does not establish that the company pays no dividend.
Up to six Polygon cash-dividend events, including recorded ex-dates within the next 120 days. Amounts retain their recorded currency and decimal precision. Historical amounts are not restated to a common split basis, annualized, or converted to dollars.
For a long holding, compare the ex-date with when you held the shares and check the pay date against your broker’s cash history. Owning the stock today does not establish past entitlement. For a short holding, a dividend can create a payment obligation to the share lender.
Ex-dates and special dividend rules · Short-sale dividend obligations · Dividend data definitions
Split history
1 for 10 · reverse split
Effective Apr 15, 2025
Each 10 pre-split shares become 1 post-split share.
Source: EODHD
1 for 5 · reverse split
Effective Mar 6, 2024
Each 5 pre-split shares become 1 post-split share.
Source: EODHD
1 for 10 · reverse split
Effective Mar 6, 2023
Each 10 pre-split shares become 1 post-split share.
Source: EODHD
250 for 5451 · reverse split
Effective Aug 15, 2003
Each 5451 pre-split shares become 250 post-split shares.
Source: EODHD
Up to six stored split dates through Nov 7, 2026. Equivalent vendor ratios are combined; conflicting ratios are left out. This history may be incomplete.
A split changes the share count and per-share price basis; it does not by itself add investment value. Put your holding’s earlier and later share counts on the same basis before comparing them. This applies to both long shares and shares owed on a short position.
How stock splits workPortfolio context
Sign in to see your position size
We’ll show you if CPHI is in your portfolio and how much it contributes.
Sign inMarket context
Loading market dates
Smart money context
Holder IQ: LOW
2 smart-money holders: institutions with a high Holder IQ
Q2 2026, filed Sep 2, 2026
Insider context
Sentiment: unknown
No recent insider trades detected.
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
No directional recent-activity label is available. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Red flags: 5
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
No directional recent-activity label is available. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Largest 13-F holders · Q2 2026
8 filers reported a long position in CPHI for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
The top 8 hold
100%
of the 203.8K shares 13-F filers reported
Moves vs Q1 2026
3 added0 trimmed
3 new · 2 unchanged
Net shares held
+479.8%
across the 5 holders with a comparable Q1 2026 book
| Rank | Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|---|
| 1 | CITADEL ADVISORS LLC | $82.8K · 125.4K shares | 125.4K | +870.6% |
| 2 | TWO SIGMA SECURITIES, LLC | $23.5K · 35.7K shares | 35.7K | New |
| 3 | RENAISSANCE TECHNOLOGIES LLC | $9.9K · 15K shares | 15K | +31.8% |
| 4 | JANE STREET GROUP, LLC | $9.2K · 13.9K shares | 13.9K | New |
| 5 | Ground Swell Capital, LLC | $7K · 10.6K shares | 10.6K | New |
| 6 | UBS Group AG | $2.1K · 3.1K shares | 3.1K | +699.2% |
| 7 | EFG International AG | $26 · 40 shares | 40 | Unchanged |
| 8 | DANSKE BANK A/S | $1 · 1 shares | 1 | Unchanged |
Sign in to see each holder’s Holder IQ, factor-adjusted Holder IQ and rank, and compare these holders with all scored filers. Available on every plan.
Sign inGet the Full Analysis for CPHI
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.